アクセス数 : ?
ダウンロード数 : ?
ID 110046
タイトル別表記
局所進行膵癌に対するゲムシタビン定速静注及びS-1併用化学放射線療法の第Ⅰ/Ⅱ相試験
FDR-gem plus S-1 with RT for pancreatic cancer
著者
池田, 敬洋 徳島大学大学院医科学教育部(医学専攻) KAKEN研究者をさがす
Takehara, Masanori University of Tokushima
Kagemoto, Kaizo University of Tokushima
Okada, Yasuyuki University of Tokushima
岡崎, 潤 University of Tokushima
Takaoka, Yoshifumi University of Tokushima
Miyamoto, Yoshihiko University of Tokushima
Matsumoto, Sayo University of Tokushima
末内, 辰尚 University of Tokushima
Takaoka, Toshi University of Tokushima
木村, 雅子 University of Tokushima
Sato, Yasuhiro Hokkaido Cancer Center
Sagawa, Tamotsu Hokkaido Cancer Center
Fujikawa, Koji Hokkaido Cancer Center
キーワード
Pancreatic cancer
Chemoradiotherapy
Fixed-dose-rate gemcitabine
S-1
gemcitabine
radiosensitizer
資料タイプ
学位論文
抄録
Purpose: This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data.
Methods: Patients with unresectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400mg/m2, 5mg/m2/min) on days 1, 8, 22, 29 and 60mg/m2 of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28fractions) was delivered concurrently.
Results: Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300mg/m2 of gemcitabine and 60mg/m2 of S-1 daily. The overall response rate was 25% and disease control rate (partial response plus stable disease) was 92%. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rate were 16.0 months and 73%, respectively.
Conclusion: The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC.
掲載誌名
Cancer Chemotherapy and Pharmacology
ISSN
03445704
14320843
cat書誌ID
AA00598397
AA1161885X
出版者
Springer nature
76
3
開始ページ
615
終了ページ
620
発行日
2015-07-29
備考
内容要旨・審査要旨・論文本文の公開:
内容要旨・審査要旨:LID201704141008.pdf
論文本文:k3028_fulltext.pdf
本論文は, 著者Takahiro Gojiの学位論文として提出され, 学位審査・授与の対象となっている。
The final publication is available at link.springer.com.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
博士論文全文を含む
文科省報告番号
甲第3028号
学位記番号
甲医第1332号
学位授与年月日
2017-03-23
学位名
博士(医学)
学位授与機関
徳島大学
部局
病院
医学系